olivLaw · US equity research
Microbot Medical Inc. MBOT
Surgical & Medical Instruments & Apparatus · SIC 3841 · Vertical: Surgical & Medical Instruments & Apparatus (SIC 3841)
Microbot Medical develops and is commercializing LIBERTY, a fully disposable robotic system for minimally invasive endovascular procedures, mainly in peripheral vessels. The company had recognized no product revenue through the end of 2025, so its commercial launch after FDA clearance in September 2025 is central to its financial outlook. Net working capital at December 31, 2025 was about $76.4 million.
At the close of 04 Nov 2026, Microbot Medical Inc. (MBOT) stock was 1.14 USD (+4.59% on the day), with market capitalisation 76.6 m USD, beta 1.77, 52-week range 0.94–2.85 USD. Latest reported quarter (Q2 2026): revenue of 241.0 k USD, net income of -5.6 m USD, diluted EPS -0.08 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 54.5
- neutral
- Bollinger (20, 2)
- 0.88 – 1.16
- in the upper half of the band · %B 0.94 · band width 26.6%
- SMA 50 / 200
- 1.22 / 1.84
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.03 / -0.07
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +6.5% | −1.1% | +7.6 pp | — |
| 3 months | −38.4% | −0.5% | −37.9 pp | — |
| 6 months | −47.9% | +4.4% | −52.3 pp | — |
| Year to date | −43.0% | +12.3% | −55.3 pp | — |
| 1 year | −43.6% | +13.5% | −57.1 pp | −5.2% |
| 3 years | −19.7% | +76.4% | −96.1 pp | +14.6% |
| 5 years | −84.4% | +63.7% | −148.1 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | 105.0 k | 241.0 k |
| Cost of revenue | — | — | — | — | — | — | 103.0 k | 884.0 k |
| Gross profit | — | — | — | — | — | — | 2.0 k | -643.0 k |
| Research & development | 2.1 m | 2.0 m | 1.5 m | 2.1 m | 1.2 m | 1.5 m | 1.3 m | 1.9 m |
| SG&A | — | — | 1.6 m | 1.6 m | — | — | 3.0 m | 3.7 m |
| Operating income | -3.3 m | -3.4 m | -3.0 m | -3.7 m | -3.9 m | -4.1 m | -4.3 m | -6.2 m |
| Depreciation & amortisation | 23.0 k ≈ | 26.0 k | 15.0 k | 12.0 k ≈ | 10.0 k ≈ | 10.0 k | 12.0 k | 15.0 k ≈ |
| Net income | -3.2 m | -3.4 m | -2.6 m | -3.5 m | -3.6 m | -3.5 m | -3.7 m | -5.6 m |
| Diluted EPS | -0.20 | -0.20 ≈ | -0.08 | -0.10 | -0.07 | -0.05 ≈ | -0.05 | -0.08 |
| Operating cash flow | -2.8 m ≈ | -1.7 m | -2.9 m | -2.6 m ≈ | -3.8 m ≈ | -3.8 m | -5.1 m | -5.0 m ≈ |
| Capex | 0 ≈ | 7.0 k | 13.0 k | 9.0 k ≈ | 13.0 k ≈ | 25.0 k | 108.0 k | 142.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Net income | -7.3 m | -7.2 m | -9.2 m | -11.3 m | -13.2 m | -10.7 m | -11.4 m | -13.1 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | -1.59 | -1.81 | -1.05 | -0.73 | -0.29 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Free cash flow | -5.5 m | -6.7 m | -7.3 m | -9.4 m | -11.6 m | -8.6 m | -8.9 m | -13.1 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 3.9 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 77.6 m USD
- Total assets
- 81.5 m USD
- Debt / equity
- unavailable
- Current ratio
- 23.33x
- ROE
- -32.4%
- ROA
- -30.0%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Research & development | 3.4 m | 6.2 m | 7.7 m | 5.7 m | 6.6 m | 6.3 m | SEC (XBRL)· 26 Mar 2026verified |
| SG&A | — | — | — | — | 5.0 m | 8.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Operating income | -9.1 m | -11.4 m | -13.3 m | -9.9 m | -11.6 m | -14.7 m | SEC (XBRL)· 26 Mar 2026verified |
| Depreciation & amortisation | 68.0 k | 76.0 k | 102.0 k | 106.0 k | 91.0 k | 47.0 k | SEC (XBRL)· 26 Mar 2026verified |
| EBITDA | -9.0 m ≈ | -11.3 m ≈ | -13.2 m ≈ | -9.7 m ≈ | -11.5 m ≈ | -14.7 m ≈ | SEC (XBRL)· 26 Mar 2026derived |
| Income tax | 0 | — | — | — | — | — | SEC (XBRL)· 31 Mar 2021verified |
| Net income | -9.2 m | -11.3 m | -13.2 m | -10.7 m | -11.4 m | -13.1 m | SEC (XBRL)· 26 Mar 2026verified |
| Diluted EPS | — | -1.59 | -1.81 | -1.05 | -0.73 | -0.29 | SEC (XBRL)· 26 Mar 2026verified |
| Weighted average diluted shares | — | — | 7.3 m | 10.2 m | 15.6 m | 45.8 m | SEC (XBRL)· 26 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 19.7 m | 13.5 m | 2.4 m | 2.5 m | 3.1 m | 3.9 m | SEC (XBRL)· 26 Mar 2026verified |
| Inventories | — | — | — | — | — | 584.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Current assets | 25.3 m | 15.9 m | 8.8 m | 7.9 m | 5.8 m | 79.8 m | SEC (XBRL)· 26 Mar 2026verified |
| Property, plant & equipment, net | 251.0 k | 244.0 k | 221.0 k | 146.0 k | 80.0 k | 93.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Total assets | 26.3 m | 16.8 m | 9.5 m | 8.3 m | 6.0 m | 81.5 m | SEC (XBRL)· 26 Mar 2026verified |
| Accounts payable | 275.0 k | 279.0 k | 116.0 k | 357.0 k | 165.0 k | 511.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Current liabilities | 1.3 m | 2.0 m | 2.1 m | 3.8 m | 2.5 m | 3.4 m | SEC (XBRL)· 26 Mar 2026verified |
| Total liabilities | 2.0 m | 2.4 m | 2.2 m | 3.8 m | 2.5 m | 4.0 m | SEC (XBRL)· 26 Mar 2026verified |
| Equity | 24.3 m † | 14.4 m † | 7.3 m † | 4.5 m † | 3.5 m † | 77.6 m † | SEC (XBRL)· 26 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -7.3 m | -9.4 m | -11.5 m | -8.5 m | -8.8 m | -13.0 m | SEC (XBRL)· 26 Mar 2026verified |
| Capex | 91.0 k | 69.0 k | 84.0 k | 33.0 k | 25.0 k | 60.0 k | SEC (XBRL)· 26 Mar 2026verified |
| Free cash flow | -7.3 m ≈ | -9.4 m ≈ | -11.6 m ≈ | -8.6 m ≈ | -8.9 m ≈ | -13.1 m ≈ | SEC (XBRL)· 26 Mar 2026derived |
| Investing cash flow | -2.8 m | 3.2 m | -3.8 m | 2.0 m | 1.5 m | -72.4 m | SEC (XBRL)· 26 Mar 2026verified |
| Financing cash flow | -3.4 m | — | 4.3 m | 6.6 m | 7.9 m | 86.2 m | SEC (XBRL)· 26 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 3 of at least 6
- score weight coverage: 20.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 76.6 m USD
Key indicators
Coverage and freshness
Score by group
21% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 3 of at least 6; score weight coverage: 20.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -56.0% | 0 (on a fixed band) | 40% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 18.6x | 100 (on a fixed band) | 20% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -23.4% | 0 (on a fixed band) | 40% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
MICROBOT MEDICAL INC. (MBOT). Latest full fiscal year: 2015; data up to 2026-06-30.
Figures computed from the financial statements: YoY growth -88.5%; ROE -32.9%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 3 of at least 6; score weight coverage: 20.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 18.6x
What contradicts it
- Revenue CAGR 3Y: -56.0%
- FCF yield: -23.4%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Surgical & Medical Instruments & Apparatus (SIC 3841) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SYKStryker Corp | 129.3 bn | 36.2 | 16.0% | 13.8% | +11.2% | −8% / +15% |
| MMM3m Company | 100.2 bn | 28.9 | 80.8% | 14.0% | +1.5% | +13% / +134% |
| BSXBoston Scientific Corporation | 66.4 bn | 19.4 | 14.3% | 16.6% | +19.9% | −55% / −18% |
| BDXBecton, Dickinson And Company | 57.0 bn | 63.2 | 3.8% | 4.0% | +8.2% | +37% / +13% |
| RMDResMed Inc. | 33.8 bn | 21.9 | 26.4% | 27.8% | +9.9% | −6% / +52% |
| DXCMDexcom, Inc. | 33.0 bn | 34.8 | 37.7% | 19.4% | +15.6% | +39% / −23% |
| WSTWest Pharmaceutical Services, Inc. | 28.5 bn | 45.9 | 21.2% | 18.8% | +6.3% | +47% / +17% |
| SOLVSolventum Corporation | 15.2 bn | 10.9 | 34.0% | 17.3% | +0.9% | +5% / unavailable |
| PENPenumbra, Inc | 12.7 bn | 81.2 | 10.7% | 10.1% | +17.5% | +10% / +45% |
| GMEDGlobus Medical, Inc. | 11.7 bn | 22.3 | 11.8% | 17.0% | +16.7% | −4% / +94% |
| TFXTeleflex Incorporated | 6.4 bn | — | -28.9% | -45.8% | +17.2% | +31% / −34% |
| HAEHaemonetics Corporation | 5.8 bn | 62.3 | 11.2% | 7.1% | −2.0% | +57% / +58% |
| MMSIMerit Medical Systems Inc | 5.4 bn | 34.0 | 9.8% | 9.9% | +11.8% | +5% / +27% |
| HTFLHeartflow, Inc. | 4.9 bn | — | — | -55.8% | +39.9% | +75% / unavailable |
| ICUIIcu Medical Inc | 4.3 bn | 144.2 | 1.4% | 1.4% | −6.3% | +16% / +97% |
| LMATLemaitre Vascular, Inc. | 2.0 bn | 30.9 | 16.8% | 25.0% | +13.5% | +6% / +67% |
| TNDMTandem Diabetes Care, Inc. | 1.3 bn | — | -48.0% | -6.1% | +7.9% | −9% / −6% |
| IARTIntegra Lifesciences Holdings Corp | 1.2 bn | 88.3 | 1.2% | 0.8% | +1.5% | +13% / −62% |
| BBNXBeta Bionics, Inc. | 921.5 m | — | -23.9% | -65.3% | +53.9% | −46% / unavailable |
| SSIISs Innovations International, Inc. | 454.9 m | — | -26.1% | -23.7% | +105.7% | −66% / unavailable |
| CARLCarlsmed, Inc. | 439.3 m | — | -6,196.9% | -57.4% | +85.9% | −1% / unavailable |
| BWAYBrainsway Ltd. | 439.0 m | 224.2 | 5.6% | 7.1% | +29.0% | +28% / +258% |
| EMBCEmbecta Corp. | 369.4 m | 4.4 | — | 8.6% | −3.8% | −49% / −64% |
| CLPTClearPoint Neuro, Inc. | 325.7 m | — | -167.5% | -79.4% | +17.8% | −30% / +76% |
| TMCITreace Medical Concepts, Inc. | 292.7 m | — | -72.0% | -29.0% | +1.6% | +51% / −49% |
1- and 3-year price returns: for MBOT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Microbot Medical develops and is commercializing LIBERTY, a fully disposable robotic system for minimally invasive endovascular procedures, mainly in peripheral vessels. The company had recognized no product revenue through the end of 2025, so its commercial launch after FDA clearance in September 2025 is central to its financial outlook 12. Net working capital at December 31, 2025 was about $76.4 million 1.
SWOT
Strengths
- A compact, disposable platform with FDA clearance and ISO 13485 certification for its quality management system 12.
- A balance sheet strengthened by 2025 equity issuances, with a sizeable net working capital at year end 1.
- An intellectual property portfolio, including NovaCross technology acquired from Nitiloop assets 2.
Weaknesses
Opportunities
Risks
- Need for additional capitalhigh
The company expects to need further funding, and difficulty raising capital could force cuts to development programs 1.
- No clear path to profitabilityhigh
There is no certainty about when, or whether, the company will become profitable, which could weigh on investor confidence 1.
- Hospital adoptionmedium
Commercial success depends on acceptance by physicians and institutions, which could be slower than expected 1.
- Outsourced manufacturingmedium
Reliance on a third-party contract manufacturer could delay deliveries or raise costs 1.
- Geopolitical riskmedium
The Middle East conflict could affect personnel and activities located in Israel 2.
Investment thesis
What would need to be true (bull case)
- If the commercial launch of the LIBERTY system expands after FDA clearance, the company could benefit from a product that is unique in its market 12.
- An intellectual property portfolio and expansion into new clinical segments could support long-term growth 2.
- If CE Mark approval arrives on schedule, access to European markets could add a new revenue source 2.
What would break the thesis
- The company has not yet generated product revenue and its cumulative losses are significant, which could limit financial flexibility 1.
- Dependence on a single product and an outside manufacturing partner could amplify execution risks 1.
- Uncertain physician adoption and reimbursement could delay the revenue the growth plan assumes 1.
What to watch
- Trajectory of revenue from the first commercial LIBERTY salesQ3 2026
- CE Mark approval and European launchsecond half of 2026
- New financing transactions and the level of net working capitalnext 10-K
- Sales and administrative spending as the commercial team expandsQ4 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Microbot Medical is a medical device company focused on next generation robotic endoluminal surgery, with the aim of improving surgical outcomes for patients 1. Its main product, the LIBERTY Endovascular Robotic Surgical System, is designed to maneuver guidewires and microcatheters within the vasculature without dedicated Cath-lab rooms. According to the 10-K, the company shifted in 2025 from research and development toward commercialization 1.
The company had not recognized product revenue through December 31, 2025 and expects significant operating losses for the foreseeable future 1. Funding has come mainly from equity issuances, exercises of preferred investment options and grants from the Israeli Innovation Authority 1. Manufacturing is handled by a third-party contract manufacturer 1.
The 10-Q for the quarter ended June 30, 2026 reports a full market release of LIBERTY at the Society of Interventional Radiology conference in April 2026, and CE Mark approval was anticipated in the second half of 2026 with no assurance given 2. The acquisition of Nitiloop assets, including NovaCross technology, broadens the product portfolio 2.
Segments
LIBERTY Endovascular Robotic Surgical System
The core platform, fully disposable, currently targeted at the peripheral interventional radiology market, with future versions expected for interventional cardiology and neuroradiology 2. Its compact design, remote operation and telecatheterization potential, which is not covered by the FDA 510(k) clearance, are its key attributes 2.
Market context
The company focuses its sales on the peripheral interventional radiology market, where it argues its system removes the need for extensive capital equipment 2. The actual size of the market is hard to predict, and penetration could be smaller than anticipated 1.
Adoption depends on acceptance by physicians, hospitals and third-party payors, notably the Centers for Medicare & Medicaid Services, which shape reimbursement 1. Without adequate reimbursement, sales could be limited 1.
Trends
- Shift to commercializationmixed
The company has moved its focus from research toward sales, which raises marketing costs but could unlock revenue if the launch succeeds 12.
- Demand for miniaturized robotic surgerytailwind
Interest in minimally invasive procedures and disposable systems supports demand for compact platforms, though robotic competition could intensify 1.
- Regulation and reimbursementmixed
FDA and CE Mark approvals, along with payor reimbursement policies, could speed up or slow adoption of the product 12.
- Geopolitical tensions in Israelheadwind
Research and development operations are based in Israel, and the regional conflict could affect the company's activities 2.
Competitive position
The company notes that competitors could develop technologies more attractive to hospitals and physicians and could hold intellectual property rights that limit its marketing 1. The sources do not explicitly name competitors.
A stated advantage is that LIBERTY is the first fully disposable robotic system for endovascular procedures, which could reduce equipment costs relative to existing systems 2.
- Large-cap surgical robotics makers
The sources say other players could launch competing technologies for the same markets, without naming them.
- Companies holding guidewire-related intellectual property
Competitors may hold patents that could prevent the company from marketing its products 1.
- Existing robotic catheterization systems
The company states that rival systems require dedicated cath-lab rooms and staff, unlike LIBERTY 2.
- Developers of telecatheterization technologies
Competition in remote procedures could become relevant if the telecatheterization feature is validated 2.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Proxy statement03 Nov 2026
- Current report27 Oct 2026Regulation FD disclosure · Financial statements and exhibits
- Current report23 Oct 2026Regulation FD disclosure · Financial statements and exhibits
- Current report20 Oct 2026Item 5.08 · Regulation FD disclosure · Financial statements and exhibits
- Current report06 Oct 2026Regulation FD disclosure · Financial statements and exhibits
- Current report28 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Current report11 Aug 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report11 Aug 2026
- Current report07 Aug 2026Material agreement · Departure or appointment of officers · Financial statements and exhibits
- Current report21 Jul 2026Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Microbot Medical Inc. · 26 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Microbot Medical Inc. · 11 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Microbot Medical Inc. · 15 Aug 2017
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.